# A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies

> **NCT01204073** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Advanced Nonhematologic Malignancies
- Carcinoma, Basal Cell

## Interventions

- **DRUG:** TAK-441

## Key facts

- **NCT ID:** NCT01204073
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-01
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204073, "A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01204073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*